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Abstract
Purpose To compare visual and refractive results of Toric
Implantable Collamer Lens (TICL) and bioptics (ICL plus
excimer corneal surgery) to treat myopic astigmatism.
Methods Eighty-one eyes underwent TICL implantation
and 83 eyes were treated with bioptics (corneal ablation
was performed between 1.5 and 6 months after ICL implan-
tation). Uncorrected distance visual acuity (UDVA), cor-
rected distance visual acuity (CDVA), refraction, adverse
events, safety, and efficacy were evaluated 12 months
postoperatively.
Results At 12 months postoperatively, the mean spherical
equivalent was −0.15±0.36 diopters (D) in the TICL group
and −0.08±0.26 D in the bioptics group (p00.099). Sixty-
six (81.5 %) and 78 (94.0 %) eyes were within ±0.50 D for
TICL and bioptics groups, respectively. The mean Snellen
UDVA was not statistically different between both proce-
dures (p00.909); 53 (65.4 %) and 54 (65.1 %) eyes
achieved at least 20/25 or better in TICL and bioptics
groups, respectively. No eye had lost more than two lines
of CDVA, and 32.1 % of eyes (26/81) in the TICL group and
57.8 % of eyes (48/83) in the bioptics group had better
postoperative UDVA than preoperative CDVA (p<0.001).
Safety was not statistically different between groups (p0
0.464) while efficacy was significantly higher in the bioptics
group (p00.000). Two eyes with a TICL were treated to
correct TICL decentration.
Conclusions Bioptics showed slightly better outcomes in
some clinical measures such as uncorrected visual acuity,
efficacy, and refractive predictability. TICL implantation
shows reliable results similar to bioptics. A single procedure
with TICL implantation might be preferred, eliminating the
inherent risks of laser treatments and the risks of a second
surgical procedure.
Keywords Implantable Collamer Lens . Bioptics . Excimer
laser
Introduction
Keratorefractive surgeries, such as photorefractive keratec-
tomy (PRK) and LASIK, have successfully been performed
to treat myopic astigmatism. Although the outcomes of the
procedure were excellent for treating mild to moderate my-
opic astigmatism, such results do not appear to be as repro-
ducible when used to correct higher levels of myopia and
astigmatism [1–3].
The Implantable Collamer Lens (Visian ICL; STAAR
Surgical, Nidau, Switzerland) is a foldable posterior phakic
intraocular lens (pIOL) that can be used to correct high
myopia up to −18.00 diopters (D) and provides stable visual
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outcomes [4–7]. Before the advent of the Toric Implantable
Collamer Lens (TICL, STAAR Surgical), the Visian ICL
could only correct the spherical component of the refractive
error and, as a result, coexisting refractive astigmatism had
to be treated by either keratorefractive procedures such as
incisional keratotomy or excimer laser ablation. Combining
surgical procedures was initially described by Zaldivar et al.
[8], who termed bioptics to the use of LASIK after pIOL
implantation to treat extreme myopia and myopia combined
with astigmatism. Some studies reported that bioptics is a
valuable option for treating residual refractive errors [9–12]
with an improved predictability and similar safety when
compared with single pIOL surgery.
Currently, toric ICL implants have demonstrated to be
safe and effective in correcting myopia with astigmatism,
with excellent visual and refractive results [13–16].
However, there is only one study that directly compares
the clinical results between TICL implantation and bioptics
[17]. The purpose of this study was to evaluate the clinical
results and compare the safety, efficacy, and predictability
between TICL implantation and bioptics to treat eyes with
moderate to high myopia with astigmatism.
Patients and methods
The medical records of 164 eyes of 106 patients who un-
derwent implantation of a Collamer pIOL to correct myopia
and astigmatism at the Fernández-Vega Ophthalmological
Institute (Oviedo, Spain) were evaluated retrospectively.
Eighty-one eyes of 53 patients underwent TICL implanta-
tion from September 2004 to April 2009 and 83 eyes of 53
patients had bioptics from June 2003 to October 2008. In the
bioptics group, data were collected from patients who had
previously undergone spherical Visian ICL (model V4) im-
plantation and subsequent residual refractive errors treated
by excimer laser between 1.5 and 6 months after ICL
implantation.
At the time of the surgery, all patients were fully in-
formed of the details and possible risks of the surgical
procedures. Written informed consent was obtained from
all patients before surgery in accordance with the
Declaration of Helsinki and the study was approved by an
institutional review board.
Exclusion criteria included clinical signs of intraocular
inflammation, endothelial dystrophy, cataract, glaucoma,
macular degeneration or retinopathy, progressive myopia,
previous intraocular surgery, age <22 years, anterior chamber
depth <2.8 mm, and endothelial cell density (ECD) <2,000
cell/mm2. Before the ICL implantation, patients had a com-
plete ophthalmologic examination, including manifest and
cycloplegic refraction, keratometry, corneal topography, and
pachymetry using the Orbscan II (Bausch&Lomb, Rochester,
NY, USA), ECD (SP 3000P; Topcon Europe Medical, The
Netherlands), slit-lamp examination, Goldmann applanation
tonometry, and binocular indirect ophthalmoscopy through
dilated pupils.
ICL size and power calculation
All eyes were implanted with the latest ICL models (ICLV4
for myopia and TICL for myopia with astigmatism). The
ICL size was individually determined based on the horizon-
tal white-to-white distance (WTW) and anterior chamber
depth (ACD) measured with Orbscan II following the man-
ufacturer’s recommendations. The size was calculated by
adding 0.5 mm to the horizontal WTW measurement.
Power calculation for both ICL was performed using the
software provided by the manufacturer using a modified
vertex formula. The ICL and TICL surgical procedure was
the same as reported previously by the authors [18–20]. In
all eyes, at least 1 week before ICL implantation, two
peripheral laser Nd:YAG iridotomies were performed . All
ICL and TICL implantations were performed through a 3.2-
mm clear corneal tunnel incision in the horizontal meridian
using peribulbar anesthesia. Cycloplegic and phenylephrine
eye drops were instilled 30 min before surgery and povi-
done–iodine 5 %, 5 min before surgery. The anterior cham-
ber was filled with sodium hyaluronate 1 % (Provisc), which
was completely removed at the end of surgery. The ICL and
Table 1 Preoperative demographics of eyes that underwent Toric Implantable Collamer Lens implantation or bioptics for the correction of myopic
astigmatism
TICL Bioptics p value
No. of eyes (patients) 81 (53) 83 (53) 0.054
M/F (eyes) 22/31 16/37 0.002
Mean age (range) (years) 32.8±6.5 (22 to 46) 30.5±5.4 (22 to 45) 0.024
Refractive sphere (D)a −5.07±2.99 (−11.00 to 0.50) −9.34±3.23 (−14.00 to −2.50) 0.000
Refractive cylinder (D)a −3.09±1.18 (−6.00 to −0.50) −2.55±1.06 (−6.00 to −0.50) 0.002
TICL Toric Implantable Collamer Lens
aValues represented as mean and standard deviation
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TICL were introduced into the anterior chamber with an
injector cartridge designed by STAAR Surgical. In TICL
implantation, to control for potential cyclotorsion when
the patient is in a supine position, the surgeon marked
the zero horizontal axis at the 3- and 9-o’clock limbus
using a marking pen with the patient sat upright at a slit
lamp. The surgeon also used a Mendez ring to measure
the required rotation from horizontal during the surgical
procedure and the lens was rotated to the required axis
using a modified intraocular spatula. Tobramycin and
dexamethasone 0.1 % (Tobradex, Alcon Laboratories,
Inc.) eye drops were used four times a day for 7 days,
after which diclofenac sodium eye drops (Voltaren;
Novartis Pharmaceuticals, Basel, Switzerland) were started
four times a day for 2 weeks. In cases of bilateral im-
plantation, the second eye was operated within the first
week after the fellow eye surgery.
Laser surgery
LASIK or PRK were performed at least 1.5 months after ICL
surgery and all the eyes showed a stable refraction and corneal
topographic pattern for at least 1.5 months before performing
LASIK or PRK. Both surgeries were done by the same
surgeon (JFA). Laser surgical techniques followed common
procedures using the IntraLase FS femtosecond laser and
Visx Star S4 (Abbott Medical Optics, Inc.) excimer laser
system. In PRK, the epithelial sheet was partially removed
from the Bowman layer after the application of 20 % alcohol
for 30 s and laser ablation was applied. LASIKwas performed
in 70 eyes and PRK in 13 eyes depending on the corneal
thickness and ablation depth of each patient. All surgical
procedures were uneventful and without post-surgical com-
plications within the follow-up time presented in this study.
Postoperative assessment
Both after ICL and after laser surgery all the patients ful-
filled the follow-up protocol in which the examination visits
were carried out at 1 day, 1 week, and 1 month, and then
every 3 months as necessary. Data obtained in each postop-
erative follow-up visit included uncorrected distance visual
acuity (UDVA), corrected distance visual acuity (CDVA),
slit-lamp examination, refraction, ECD, fundus examina-
tion, intra-ocular pressure (IOP), and central separation be-
tween the lens anterior surface and the posterior surface of
the ICL (Vault) were performed. For averaging, visual acu-
ities were converted to logMAR values; then, the means and
standard deviations were back-calculated to Snellen acuity.
Sphero-cylindrical refractive results were converted into vec-
tors expressed by three dioptric powers:M, J0, and J45; withM
being equal to the spherical equivalent (SE) of the given
refractive error, and J0 and J45 the two Jackson crossed cylin-
ders equivalent to the conventional cylinder. Manifest refrac-
tions in conventional script notation (S [sphere], C [cylinder],
α [axis]) were converted to power vector coordinates and
overall blurring strength using the formulas described by
Fig. 1 Preoperative (preop) versus 12-month postoperative refractive
cylinder in diopters (D) after TICL implantation and bioptics
Table 2 Mean values of vectorial decomposition components before and after TICL implantation and bioptics
Preoperative 12 months postoperative
TICL Bioptics p value TICL Bioptics p value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
M −6.62±2.84 −10.61±3.27 0.000 −0.15±0.36 −0.08±0.26 0.099
J0 0.87±1.16 0.89±0.80 0.410 0.09±0.22 0.02±0.12 0.030
J45 0.02±0.81 0.02±0.69 0.984 −0.01±0.16 0.01±0.11 0.911
BOLD the difference between groups is statistically significant
TICL Toric Implantable Collamer Lens; J0 Jackson cross-cylinder, axes at 180° and 90°; J45 Jackson cross-cylinder, axes at 45° and 135°; M
spherical equivalent
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Thibos and Horner [21]: M 0 S + C/2; J0 0 (−C/2)*cos (2α);




Data analysis was performed using SPSS for Windows
version 16.01 (SPSS Inc. Chicago, IL, USA). Normality of
data was checked by Kolmogorov–Smirnov test and ana-
lyzed using the Wilcoxon rank-sum test and Mann–Whitney
U test to explore statistical differences for refractive and
visual acuity scores among different groups (TICL vs. bio-
ptics). Bivariate correlations between attempted versus
achieved refraction was analyzed using non-parametric
(Spearman’s coefficient) correlation analysis. Differences
were considered to be statistically significant when the p
value was <0.05.
Results
The mean age of the 53 patients of each group was
32.8 years ± 6.5 (SD) (range 22 to 46 years) and 30.5±5.4
in the TICL and bioptics group, respectively. In the bioptics
group, corneal ablations were performed at 4.13±
1.17 months (range: 1.5 to 6 months) after ICL implantation
by LASIK in 70 eyes and PRK in 13 eyes. Mean follow-up
was 12.9±5.4 months (range: 6 to 23 months) in the TICL
group and 12.7±4.2 months (range: 5 to 20 months) in the
bioptics group. Preoperative descriptive statistics including
age and refraction for both groups is shown in Table 1. In
the bioptics group, mean SE and refractive cylinder after
ICL implantation and prior to excimer laser treatment were
−0.56±0.63 D (range: −2.00 to 1.00 D) and −1.26±0.86 D
(range: −3.75 to 0.00 D), respectively.
Refractive outcomes
Figure 1 presents the distribution of the manifest refractive
cylinder before both surgeries compared with the 12-month
visit outcomes. There were no significant differences in
outcomes between eyes treated with LASIK and eyes treated
with PRK. At the 12-month follow-up visit, 76 (93.8 %) and
81 (97.6 %) of eyes had ≤1.0 D of cylinder for TICL and
bioptics groups, respectively. Furthermore, only one eye in
each group had preoperative refractive cylinder of 0.50 D,
whereas 61 (75.3 %) and 80 (96.4 %) had ≤0.5 D of
postoperative refractive cylinder for TICL and bioptics
groups, respectively.
The distribution of the refractive components after vector
conversion, before and after the different surgical proce-
dures, is shown in Table 2. Despite that the mean preoper-
ative refractive cylinder was statistically different between
groups, there were no statistically significant differences in
J0 and J45 astigmatic components. At 12 months postoper-
atively, mean preoperative manifest SE improved from
−6.62±2.83 D to −0.15±0.36 D in the TICL group and
from −10.61±3.27 D to −0.08±0.26 D in the bioptics group.
The difference was not statistically significant for M (SE)
and J45 component (p00.099 and p00.911, respectively).
Figure 2a and b shows the 12-month results for the
astigmatic components of the power vector as represented
by the two-dimensional vector plot (J0, J45). It is visible the
spread of data preoperatively and the concentration of data
around the origin (0,0 coordinates) after both procedures.
Fig. 2 Scatter plot of the astigmatic vectors (J0 and J45) before and
after TICL (a) and bioptics (b) treatment. The more central location of
postoperative data represents the reduction of preoperative astigmatism
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Distribution of SE after both surgical procedures is shown in
Fig. 3. The percentage of eyes with SE within 0.50 D and 1.00
D was higher in the bioptics group than in the TICL group and
all eyes of both groups had a SE lower than 2.0 D. Sixty-six
(81.5 %) and 78 (94.0 %) eyes were within ±0.50 D for SE
component for TICL and bioptics groups, respectively; 79
(97.5 %) and 82 (98.8 %) eyes were within ±1.00 D of the
desired refraction (r200.98 and r200.99 for attempted vs.
achieved correlation analysis, for TICL and bioptics group,
respectively). For J0 astigmatic component, 78 (96.3 %) and
81 (97.6 %) eyes were within ±1.00 D (r200.96 and r200.98
for TCIL and bioptics, respectively) while for the J45 compo-
nent 78 (96.3 %) and 82 (98.8 %) eyes were within ±1.00 D
(r200.94 and r200.98 for TCIL and bioptics, respectively), as
shown in Fig. 4a, b and c, respectively.
Visual outcomes
Table 3 presents pre-and postoperative visual outcomes. The
results were similar or better in the TICL group than those of
the bioptics group in terms of visual acuity. At 12 months,
no statistical difference was noted in mean UDVA between
the two groups (0.81±0.21 vs. 0.81±0.17 for TICL and
bioptics respectively, p00.909), however, mean CDVA
was significantly better in the TICL group (0.90±0.14 vs.
0.84±0.15 for TICL and bioptics, respectively, p0 .016).
Efficacy index (mean postoperative UDVA/mean preopera-
tive CDVA) was significantly higher in bioptics (p<.001),
while the differences in safety index (mean postoperative
CDVA/mean preoperative CDVA) were not statistically sig-
nificant between the two groups (p00.464).
Fig. 4 Plots of achieved correction against attempted correction
(predictability) as spherical equivalent (M) (a) and the astigmatic
components J0 (b) and J45 (c) in diopters (d) in TICL and bioptics
groups
Fig. 3 Twelve month postoperative distribution of spherical equiva-
lent (SE) in diopters (D) for TICL implantation and bioptics
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Mean postoperative UDVAwas 20/63 or better in all eyes
in either groups, with 53 (65.4 %) and 54 (65.1 %) eyes
achieving at least 20/25 or better in TICL group (Fig. 5) and
bioptics group (Fig. 6), respectively (p00.0909). Mean post-
operative CDVA was 20/40 or better in all eyes in either
groups, with 44 (54.3 %) and 27 (32.5 %) eyes achieving at
least 20/20 or better in TICL and bioptics group, respectively
(p<0.001).
Changes in CDVA (safety) after both procedures are shown
in Fig. 7. In the TICL group, no eye had lost more than two
lines of CDVA, 1 (1.2 %); 2 (2.5 %) eyes lost two and one
lines while in the bioptics group 2 (2.4 %) and four (4.8 %)
eyes lost two lines and one line, respectively. Seventy-eight
eyes (96.3 %) in TICL and 77 eyes (92.8 %) in bioptics
achieved improved CDVA compared with CDVA at baseline,
(p00.414), and 32.1 % of eyes (26/81) in the TICL and
57.8 % of eyes (48/83) in the bioptics group gained better
postoperative UDVA than preoperative CDVA (p<0.001).
Adverse events
There were no intraoperative complications. There were no
cases of pupillary block or anterior subcapsular cataract
during the follow-up period of the study. In the bioptics
group, no dehiscence was observed in the ICL incision or
dislocation or decentration of the ICL due to laser treatment.
Fig. 5 Preoperative cumulative CDVA Snellen acuity versus postop-
erative UDVA after TICL implantation
Fig. 6 Preoperative cumulative CDVA Snellen acuity versus postop-
erative UDVA after bioptics
Table 3 Pre- and postoperative visual outcomes in eyes that underwent Toric Implantable Collamer Lens implantation (n081) or bioptics (n083)
for the correction of myopic astigmatism
UDVA CDVA
TICL Bioptics p value TICL Bioptics p value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Preoperative – – – 0.82±0.17 0.75±0.19 0.012
(0.4 to 1.0) (0.2 to 1.0)
Postoperative 0.81±0.21 0.81±0.17 0.909 0.90±0.14 0.84±0.15 0.016
(0.4 to 1.0) (0.4 to 1.0) (0.4 to 1.0) (0.5 to 1.0)
Safety index 1.12±0.17 1.14±0.18 0.464
(0.75 to 1.75) (0.75 to 1.75)
Efficacy index 0.98±0.20 1.09±0.19 0.000
(0.50 to 1.75) (0.50 to 1.75)
Values represented as mean ± standard deviation (range)
TICL Toric Implantable Collamer Lens, CDVA corrected distance visual acuity, UDVA uncorrected distance visual acuity
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Two eyes in the TICL group were re-treated to correct TICL
decentration.
Discussion
Some studies have reported visual and refractive outcomes
after bioptics [8, 9, 11, 12] and TICL implantation [13–16]
and have shown those procedures as effective and safe to
correct moderate to high myopic astigmatism. However,
there are few studies reporting whether TICL implantation
is as effective as bioptics [17].
In the present study, postoperative UDVA and CDVA
were similar between TICL and bioptics, although only
CDVA was statistically better in the TICL group (p0
0.016). TICL implantation was comparable to bioptics in
terms of safety and efficacy, although efficacy index was
significantly higher in the bioptics group (0.98±0.20 vs.
1.09±0.19 for TICL and bioptics, respectively, p<0.001).
These slightly better results for efficacy index in bioptics
may be explained by the small residual uncorrected astig-
matism of about 1.0 D that was observed in the TICL group.
This may be due to a slight misalignment of the TICL,
particularly in eyes with high refractive cylinder in which
a slight misalignment may significantly worsen UDVA.
With regard to predictability, TICL implantation and bio-
ptics showed excellent and comparable results, although
only J0 astigmatic component was significantly better in
the bioptics group (p00.030). Postoperative spherical equiv-
alent was reduced from a mean −6.62±2.83 D to −0.15±
0.36 D for TICL and −10.61±3.27 D to −0.08±0.26 D in
bioptics, with 81.5 % and 94.0 % of eyes within ±0.50 D of
the predicted refraction in TICL and bioptics, respectively.
Frequently, the treatment of high myopia with astigma-
tism needs the combined use of different surgical procedures
to achieve optimal refractive results. Concepts such as bio-
ptics and adjustable refractive surgery refer to this combi-
nation. In 1999, Zaldivar et al. [8] used LASIK to correct the
residual refractive error after ICL implantation for high
myopia. They reported a mean postoperative spherical equiv-
alent and refractive cylinder of −0.20±0.90 D and −0.50±
0.50 D, respectively, with 67 % of eyes within ±0.50 D of
emmetropia. Sánchez-Galeana et al. [9] successfully per-
formed LASIK or PRK in 37 eyes implanted with an ICL
for high myopia and final refraction was within ±0.50 D in
83.7 % of eyes. In another study, Arne et al. [10] reported an
improvement in UDVA in all eyes after bioptics; however, a
loss of one line of CDVA occurred in 22.2 % of PRK-treated
eyes and in 13.6 % of LASIK-treated eyes after ICL implan-
tation. In the present study, bioptics showed similar visual and
refractive results when compared to TICL implantation, how-
ever, bioptics requires time due to the interval between the two
surgical procedures (mean 4.13 months in our study) and the
patients’ eyes are exposed to the inherent risks of a double
surgical procedure.
As mentioned above, in recent years, toric ICLs have
been shown to be effective for the correction of high myopic
astigmatism. In the FDA toric ICL clinical study [13], the
majority of the patients had postoperative UCVA better than
or equal to their preoperative CDVAwith more than 95 % of
eyes within ±1.0 D of intended refraction; adverse advents
such as TICL rotation and clinically significant lens opacity
occurred in a small percentage of eyes and were successfully
treated with no loss in CDVA. Better refractive results were
obtained in the present study for TICL group, although the
mean preoperative astigmatism was significantly higher
than in the FDA toric ICL cohort (3.09±1.18 D vs. 1.93±
0.84). When compared with laser refractive treatments, toric
ICLs performed better than PRK [22], LASIK [23], or
wavefront-guided LASIK [24], besides, a toric ICL can be
easily and safely repositioned even if improper alignment of
the axis happens, as occurred with two toric ICLs in the
present study.
Choi et al. [17] recently compared the clinical results
between TICL implantation and bioptics to correct myopia
and astigmatism and reported better visual outcomes for the
TICL group with a large proportion of eyes gained better
postoperative UDVA than preoperative CDVA. In addition,
they reported a higher proportion of SE change >0.50 D
from 1 to 12 months in the bioptics procedure. In the present
study, we found similar results regarding visual acuity;
however, our results seem to be better regarding refractive
outcomes. Although we have not analyzed stability of the
refraction over different months, it will probably have sim-
ilar behavior once bioptics is likely to involve greater and
longer corneal wound healing.
Fig. 7 Changes in CDVA (safety) in the TICL and bioptics groups
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A limitation of the present study is that both groups were
very different regarding preoperative characteristics of age,
gender, refractive sphere, and refractive cylinder, and should
be taken into account in the interpretation of the present
results. In fact, the higher number of eyes gaining lines of
visual acuity observed in the bioptics group may be
explained by the a priori higher myopia in this group, which
in turn may reflect the result of magnification of the retinal
image by eliminating the spectacle-induced minification that
those patients experience preoperatively. However, astigma-
tism correction was the main issue with both procedures
and, despite the differences in preoperative refractive cylin-
der magnitude, we do not observed significant differences
for postoperative J0 and J45 astigmatic components, which
better reflects the statistical comparability between both
groups preoperatively.
Increased intraocular pressure, pupillary block, and cata-
ract formation, have been the most documented safety con-
cerns related to ICL implantation [25–27]. Frequently it has
been associated with the physical interaction between the
ICL and crystalline lens or with the iris. Sánchez-Galeana
[9] reported the development of anterior subcapsular opac-
ities in three eyes several weeks after excimer laser surgery
in eyes containing ICL for high myopia. They also reported
ocular hypertension and macular hemorrhage in one eye
each. Choi et al. [17] reported two crystalline lens opacities
after bioptics and they assume to be due to low vaulting of
the implanted ICL. In the present study, there were no cases
of chronic elevated postoperative IOP or cataract develop-
ment, but the relatively short follow-up should be consid-
ered as a limitation. In fact, the duration of follow-up should
be taken into consideration given that the occurrence of
cataract is higher in patients with longer follow-up [25,
27]. Furthermore, it has been reported that vaulting has a
tendency to decrease over time leading to an increased risk
of cataract formation, while further mechanical contact be-
tween the ICL and the iris was considered as the most
important cause of later increased IOP events. Another
limitation of the present study is that we do not evaluate
the exact position of the ICL in the sulcus and, by this, we
cannot accurately predict if there was a slight misalignment
in the TICL or a slight rotation of the TICL overtime that
may explain some less good results in the TICL group.
The goal of refractive surgery is to achieve emmetropia
through any corrective procedure and therefore the existence
of toric IOLs became essential. Both TICL implantation and
bioptics showed good clinical results in patients with myo-
pic astigmatism, reducing preoperative spherical and astig-
matic errors with high predictability and safety. Despite that
the bioptics procedures showed slightly better outcomes in
some clinical measures such as uncorrected visual acuity,
efficacy, and refractive predictability, TICL implantation
may result in a more effective procedure since it avoids
subsequent laser ablation and therefore eliminates the risks
of a second procedure or changes in the optical quality of
the cornea through laser ablation.
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